United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,273	11/03/2003	Otmar Klingler	DEAV20020070USNP	4505
5487 75	7590 05/19/2006		EXAMINER	
ROSS J. OEH	LER ARMACEUTICALS IN	BALASUBRAMANIAN, VENKATARAMAN		
1041 ROUTE 2		C.	ART UNIT	PAPER NUMBER
MAIL CODE: 1		1624		
BRIDGEWATI	ER, NJ 08807		DATE MAILED: 05/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
Office Action Summary		10/700,273	KLINGLER ET AL.	
		Examiner	Art Unit	
		Venkataraman Balasubramanian	1624	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address	
WHIC - Exter after - If NO - Failu Any i	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES and time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	I. tely filed the mailing date of this communication. (35 U.S.C. § 133).	
Status				
2a)⊠	Responsive to communication(s) filed on <u>27 Fe</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Dispositi	on of Claims			
5)□ 6)⊠ 7)□	Claim(s) 1-7 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-7 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or			
Applicati	on Papers			
10)□	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti The oath or declaration is objected to by the Ex	epted or b) objected to by the Edrawing(s) be held in abeyance. See ton is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority u	ınder 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
Attachmen				
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date 11/25/05	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa		

Art Unit: 1624

DETAILED ACTION

Applicants' response, which included cancellation of claims 8-12 and amendment to claims 1,2 and 7, filed on 2/27/2006, is made of record. Claims 1-7 are now pending.

In view of applicants' response, all 112 second and first paragraph rejection made in the previous office action has been obviated or rendered moot by cancellation of claims.

As for the prior art rejection over Barvian et al., it should be noted that Barvian et al. is a competent 102 (b) reference as it has published date 8/21/2002, which is well before the effective filing date 3/21/2003 of applicants.

However, in view of applicant's amendment, all prior art rejections over Barvian et al., and Baader et al., have been deemed as obviated.

However, the following rejection made in the previous office action remains.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Application/Control Number: 10/700,273

Art Unit: 1624

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-7 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 6,933,298. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter namely pyrimidine dicarboxamides, composition and the method of use embraced in the instant claims overlap with those embraced in the commonly assigned US patent 6,933,298.

This rejection is same as made in the previous office action except that it includes only pending claims. Applicants have differed filing a Terminal Disclaimer.

Hence, the rejection is maintained.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/700,273

Art Unit: 1624

Any inquiry concerning this communication from the examiner should be

Page 4

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571)

272-0662. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

James O. Wilson, whose telephone number is 571-272-0661.

The fax phone number for the organization where this application or proceeding

is assigned (571) 273-8300. Any inquiry of a general nature or relating to the status of

this application or proceeding should be directed to the receptionist whose telephone

number is (571) 272-1600.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAG. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-2 17-9197 (toll-free).

Penkataraman Balasubramanian

5/12/2006